Literature DB >> 24067406

Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA.

M Campo1, A Shrestha2, E Oren2, H Thiede2, J Duchin2, M Narita1, K Crothers1.   

Abstract

The impact of hepatitis C virus infection (HCI), the most common bloodborne virus infection in the USA, on outcome of active tuberculosis (TB) treatment is largely unknown. We aimed to describe characteristics of TB patients with hepatitis C virus infection (TB-HCI) in King County, Washington, including TB treatment duration and outcome. We reviewed 1510 records of patients treated for active TB at the Public Health - Seattle & King County Tuberculosis Control Program between 2000 and 2010, and identified 53 with HCI. Advanced age, being born in the USA, HIV infection, homelessness and injection drug use were independently associated with HCI in TB cases. Independent factors associated with increased treatment duration included HIV infection, excess alcohol use, extrapulmonary TB, and any drug-resistant TB disease. Our findings suggest that TB-HCI patients can be successfully treated for active TB without extending treatment duration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24067406      PMCID: PMC9151201          DOI: 10.1017/S0950268813002355

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  25 in total

1.  Predictors of failure in timely tuberculosis treatment completion, United States.

Authors:  K Mitruka; C A Winston; T R Navin
Journal:  Int J Tuberc Lung Dis       Date:  2012-06-05       Impact factor: 2.373

2.  Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.

Authors:  Gerald Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

Review 3.  An official ATS statement: hepatotoxicity of antituberculosis therapy.

Authors:  Jussi J Saukkonen; David L Cohn; Robert M Jasmer; Steven Schenker; John A Jereb; Charles M Nolan; Charles A Peloquin; Fred M Gordin; David Nunes; Dorothy B Strader; John Bernardo; Raman Venkataramanan; Timothy R Sterling
Journal:  Am J Respir Crit Care Med       Date:  2006-10-15       Impact factor: 21.405

4.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

5.  Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy.

Authors:  Yong Soo Kwon; Won-Jung Koh; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

6.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

Review 7.  Global burden of disease (GBD) for hepatitis C.

Authors: 
Journal:  J Clin Pharmacol       Date:  2004-01       Impact factor: 3.126

8.  Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients.

Authors:  Mark H Kuniholm; Jennifer Mark; Malvina Aladashvili; N Shubladze; G Khechinashvili; Tengiz Tsertsvadze; Carlos del Rio; Kenrad E Nelson
Journal:  Int J Infect Dis       Date:  2007-07-23       Impact factor: 3.623

9.  Treatment duration for patients with drug-resistant tuberculosis, United States.

Authors:  Carla A Winston; Kiren Mitruka
Journal:  Emerg Infect Dis       Date:  2012-07       Impact factor: 6.883

10.  Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand.

Authors:  Chawin Sirinak; Wanitchaya Kittikraisak; Duangporn Pinjeesekikul; Pricha Charusuntonsri; Phinai Luanloed; La-ong Srisuwanvilai; Sriprapa Nateniyom; Somsak Akksilp; Sirirat Likanonsakul; Wanchai Sattayawuthipong; Channawong Burapat; Jay K Varma
Journal:  BMC Public Health       Date:  2008-07-18       Impact factor: 3.295

View more
  2 in total

1.  Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000-2010.

Authors:  G Bushnell; N L Stennis; A M Drobnik; D C Proops; S D Ahuja; K Bornschlegel; J Fuld
Journal:  Epidemiol Infect       Date:  2014-11-12       Impact factor: 4.434

2.  Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis.

Authors:  Meysam Behzadifar; Sanaz Heydarvand; Masoud Behzadifar; Nicola Luigi Bragazzi
Journal:  Ethiop J Health Sci       Date:  2019-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.